{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Budgett RF"],"pubmed_abstract":["The type 5 metabotropic glutamate receptor, mGlu<sub>5</sub>, has been proposed as a potential therapeutic target for the treatment of several neurodegenerative diseases. In preclinical neurodegenerative disease models, novel allosteric modulators have been shown to improve cognitive performance and reduce disease-related pathology. A common pathological hallmark of neurodegenerative diseases is a chronic neuroinflammatory response, involving glial cells such as astrocytes and microglia. Since mGlu<sub>5</sub> is expressed in astrocytes, targeting this receptor could provide a potential mechanism by which neuroinflammatory processes in neurodegenerative disease may be modulated. This review will discuss current evidence that highlights the potential of mGlu<sub>5</sub> allosteric modulators to treat neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Furthermore, this review will explore the role of mGlu<sub>5</sub> in neuroinflammatory responses, and the potential for this G protein-coupled receptor to modulate neuroinflammation."],"journal":["Frontiers in pharmacology"],"pagination":["893422"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9130574"],"repository":["biostudies-literature"],"pubmed_title":["Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?"],"pmcid":["PMC9130574"],"pubmed_authors":["Bakker G","Bradley SJ","Budgett RF","Sergeev E","Bennett KA"],"additional_accession":[]},"is_claimable":false,"name":"Targeting the Type 5 Metabotropic Glutamate Receptor: A Potential Therapeutic Strategy for Neurodegenerative Diseases?","description":"The type 5 metabotropic glutamate receptor, mGlu<sub>5</sub>, has been proposed as a potential therapeutic target for the treatment of several neurodegenerative diseases. In preclinical neurodegenerative disease models, novel allosteric modulators have been shown to improve cognitive performance and reduce disease-related pathology. A common pathological hallmark of neurodegenerative diseases is a chronic neuroinflammatory response, involving glial cells such as astrocytes and microglia. Since mGlu<sub>5</sub> is expressed in astrocytes, targeting this receptor could provide a potential mechanism by which neuroinflammatory processes in neurodegenerative disease may be modulated. This review will discuss current evidence that highlights the potential of mGlu<sub>5</sub> allosteric modulators to treat neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, Parkinson's disease, and amyotrophic lateral sclerosis. Furthermore, this review will explore the role of mGlu<sub>5</sub> in neuroinflammatory responses, and the potential for this G protein-coupled receptor to modulate neuroinflammation.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-04T19:31:35.693Z","creation":"2025-02-19T02:57:51.179Z"},"accession":"S-EPMC9130574","cross_references":{"pubmed":["35645791"],"doi":["10.3389/fphar.2022.893422"]}}